Kiora Pharmaceuticals, Inc.
KPRX Healthcare Biotechnology
Kiora Pharmaceuticals, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $16.0 million. In the quarter to June 2026, EPS grew 37.0% and free cash flow grew 50.1%, each against the same quarter a year earlier.
Follow KPRX
Kiora Pharmaceuticals, Inc. (KPRX) EV/Sales
As of 16 October 2026, Kiora Pharmaceuticals, Inc. (KPRX) trades at a EV/Sales of −0.1×. Over the past ten years it has ranged from −4.3× (March 2018) to 74.9× (June 2022); the current reading is higher than 30% of that period. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2024 | −0.7× | — |
| FY2020 | 6.7× | 3.96% |
| FY2019 | 6.4× | 29.94% |
| FY2018 | 5.0× | (64.44%) |
| FY2017 | 14.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2024 | −0.5× | — |
| Mar 2024 | −0.8× | — |
| Dec 2020 | 6.7× | 219.38% |
| Mar 2019 | 2.1× | (20.74%) |
| 9 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| PHIO Phio Pharmaceuticals Corp. compare | −19.5× |
| KPRX Kiora Pharmaceuticals, Inc. | −0.1× |
| INTS Intensity Therapeutics Inc. compare | n/m |
| CLRB Cellectar Biosciences, Inc. compare | n/m |
| LTRN Lantern Pharma Inc. compare | n/m |
| GDTC CytoMed Therapeutics Limited compare | n/m |
| PTN Palatin Technologies, Inc. compare | 0.7× |
| BLRX BioLineRx Ltd. compare | 1.9× |
| TPST Tempest Therapeutics, Inc. compare | 33.7× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)